LONDON-- GlaxoSmithKline PLC (GSK.LN) Friday said it plans to submit a marketing authorization application to the European Medicines Agency for its candidate shingles vaccine Shingrix to be used in people aged 50 years or over.

Shares at 1338 GMT, up 14 pence, or 1%, at 1,538 pence valuing the company at GBP75 billion.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

November 25, 2016 08:55 ET (13:55 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.